Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

A2AR Antagonism with CPI-444 Induces Anti-Tumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models.

Willingham SB, Ho PY, Hotson A, Hill CM, Piccione EC, Hsieh J, Liu L, Buggy JJ, McCaffery I, Miller RA.

Cancer Immunol Res. 2018 Aug 21. pii: canimm.0056.2018. doi: 10.1158/2326-6066.CIR-18-0056. [Epub ahead of print]

PMID:
30131376
2.

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer.

Betancur PA, Abraham BJ, Yiu YY, Willingham SB, Khameneh F, Zarnegar M, Kuo AH, McKenna K, Kojima Y, Leeper NJ, Ho P, Gip P, Swigut T, Sherwood RI, Clarke MF, Somlo G, Young RA, Weissman IL.

Nat Commun. 2017 Apr 5;8:14802. doi: 10.1038/ncomms14802.

3.

Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine tumors.

Krampitz GW, George BM, Willingham SB, Volkmer JP, Weiskopf K, Jahchan N, Newman AM, Sahoo D, Zemek AJ, Yanovsky RL, Nguyen JK, Schnorr PJ, Mazur PK, Sage J, Longacre TA, Visser BC, Poultsides GA, Norton JA, Weissman IL.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4464-9. doi: 10.1073/pnas.1600007113. Epub 2016 Mar 31. Erratum in: Proc Natl Acad Sci U S A. 2016 Sep 13;113(37):E5538.

4.

Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity.

Huang W, Seo J, Willingham SB, Czyzewski AM, Gonzalgo ML, Weissman IL, Barron AE.

PLoS One. 2014 Feb 28;9(2):e90397. doi: 10.1371/journal.pone.0090397. eCollection 2014.

5.

Isolation and mutational analysis of circulating tumor cells from lung cancer patients with magnetic sifters and biochips.

Earhart CM, Hughes CE, Gaster RS, Ooi CC, Wilson RJ, Zhou LY, Humke EW, Xu L, Wong DJ, Willingham SB, Schwartz EJ, Weissman IL, Jeffrey SS, Neal JW, Rohatgi R, Wakelee HA, Wang SX.

Lab Chip. 2014 Jan 7;14(1):78-88. doi: 10.1039/c3lc50580d.

6.

Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response.

Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA, Weiskopf K, Miyanishi M, Weissman IL.

Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103-8. doi: 10.1073/pnas.1305569110. Epub 2013 May 20.

7.

Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth.

Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, Fletcher JA, West RB, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3501-6. doi: 10.1073/pnas.1222893110. Epub 2013 Feb 4.

8.

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells.

Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL.

Leukemia. 2012 Dec;26(12):2538-45. doi: 10.1038/leu.2012.141. Epub 2012 May 30.

PMID:
22648449
9.

Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma.

Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6656-61. doi: 10.1073/pnas.1121629109. Epub 2012 Mar 26.

10.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7. doi: 10.1073/pnas.1121623109. Epub 2012 Mar 26.

11.

Three differentiation states risk-stratify bladder cancer into distinct subtypes.

Volkmer JP, Sahoo D, Chin RK, Ho PL, Tang C, Kurtova AV, Willingham SB, Pazhanisamy SK, Contreras-Trujillo H, Storm TA, Lotan Y, Beck AH, Chung BI, Alizadeh AA, Godoy G, Lerner SP, van de Rijn M, Shortliffe LD, Weissman IL, Chan KS.

Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2078-83. doi: 10.1073/pnas.1120605109. Epub 2012 Jan 19. Erratum in: Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3600.

12.

Cutting edge: NLRC5-dependent activation of the inflammasome.

Davis BK, Roberts RA, Huang MT, Willingham SB, Conti BJ, Brickey WJ, Barker BR, Kwan M, Taxman DJ, Accavitti-Loper MA, Duncan JA, Ting JP.

J Immunol. 2011 Feb 1;186(3):1333-7. doi: 10.4049/jimmunol.1003111. Epub 2010 Dec 29.

13.

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL.

Sci Transl Med. 2010 Dec 22;2(63):63ra94. doi: 10.1126/scitranslmed.3001375.

14.

NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways.

Willingham SB, Allen IC, Bergstralh DT, Brickey WJ, Huang MT, Taxman DJ, Duncan JA, Ting JP.

J Immunol. 2009 Aug 1;183(3):2008-15. doi: 10.4049/jimmunol.0900138. Epub 2009 Jul 8.

15.

Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate the signaling activities of the NLRP3 and ASC-containing inflammasome.

Duncan JA, Gao X, Huang MT, O'Connor BP, Thomas CE, Willingham SB, Bergstralh DT, Jarvis GA, Sparling PF, Ting JP.

J Immunol. 2009 May 15;182(10):6460-9. doi: 10.4049/jimmunol.0802696.

16.

Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and ASC speck formation induced by Porphyromonas gingivalis in human cells.

Huang MT, Taxman DJ, Holley-Guthrie EA, Moore CB, Willingham SB, Madden V, Parsons RK, Featherstone GL, Arnold RR, O'Connor BP, Ting JP.

J Immunol. 2009 Feb 15;182(4):2395-404. doi: 10.4049/jimmunol.0800909.

17.

NLRs and the dangers of pollution and aging.

Willingham SB, Ting JP.

Nat Immunol. 2008 Aug;9(8):831-3. doi: 10.1038/ni0808-831. No abstract available.

18.

Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3.

Li H, Willingham SB, Ting JP, Re F.

J Immunol. 2008 Jul 1;181(1):17-21.

19.

NLRs at the intersection of cell death and immunity.

Ting JP, Willingham SB, Bergstralh DT.

Nat Rev Immunol. 2008 May;8(5):372-9. doi: 10.1038/nri2296. Review.

PMID:
18362948
20.

Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC.

Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, Duncan JA, Barnoy S, Venkatesan MM, Flavell RA, Deshmukh M, Hoffman HM, Ting JP.

Cell Host Microbe. 2007 Sep 13;2(3):147-59.

21.

Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling.

Duncan JA, Bergstralh DT, Wang Y, Willingham SB, Ye Z, Zimmermann AG, Ting JP.

Proc Natl Acad Sci U S A. 2007 May 8;104(19):8041-6. Epub 2007 May 2.

Supplemental Content

Loading ...
Support Center